Tumors in the thymus can be of different cellular origin. Among the most common tumors are thymoma and lymphoma, which are derived from transformed thymic epithelial cells and transformed lymphocytes, respectively. Thymic lymphoma and their response to apoptotic stimuli are poorly characterized. Here, we analyse apoptosis events in the thymic lymphoma cell line Thy278, which expresses cell surface antigens characteristic of immature double positive thymocytes. Upon T-cell receptor (TCR)/ CD3 stimulation, Thy278 cells die by apoptosis, similar as primary thymocytes during negative selection. Caspases are crucial for deletion of both Thy278 cells and normal thymocytes. Moreover, we show that deletion of primary thymocytes and Thy278 cells upon CD3 stimulation is considerably impaired by neutralizing CD95L antibody. Thus, our results not only demonstrate that TCR-induced apoptosis is still functional in transformed thymocytes, but also suggest that Thy278 cells are a helpful model for the molecular analysis of negative selection.
Introduction
Normal, non-transformed T cells develop in the thymus through different stages that can be characterized by surface expression of CD4 and CD8. Bone marrowderived hematopoietic stem cells mature via CD4 À CD8 À double negative (DN) and CD4 þ CD8 þ double positive (DP) cells to CD4 þ or CD8 þ single positive (SP) thymocytes. At the late DN stage, T-cell receptor (TCR) gene segments rearrange by a stochastic mechanism involving combinatorial diversity capable of generating about 10 18 different ab TCRs (Davis and Bjorkman, 1988) . As this process generates self-reactive TCRs, however, autoreactive T cells must be deleted from the repertoire through a process, called negative selection. This selection process acts predominantly at the CD4 þ
CD8
þ DP stage of T-cell development, when thymocytes expressing TCRs with a strong affinity to peptide/ major histocompatibility complexes (MHCs) are eliminated by induction of transcription-dependent apoptosis (Starr et al., 2003; Venanzi et al., 2004) .
In addition to the probability of producing autoreactive cells, the rearrangement of TCR genes during development in the thymus makes thymocytes also susceptible towards chromosomal abnormalities such as translocations and inversions, which can contribute to tumor formation (Boehm and Rabbitts, 1989) . Many different types of tumors can arise in the thymus including thymoma, thymic carcinoma, germ cell tumors, thymic carcinoid tumors and lymphoma. The most common thymic tumors are thymoma and lymphoma (Chahinian, 2003) . Thymomas are characterized by neoplastic-transformed thymic epithelial cells mixed with normal lymphocytic cells (Rosai and Levine, 1976) . These tumors are usually slow growing and are often associated with autoimmune disorders such as myasthenia gravis (Rosai and Levine, 1976; Namba et al., 1978) . Lymphomas in the thymus may be Hodgkin's disease, large-cell lymphoma or lymphoblastic lymphoma (Aisenberg, 1993) . In mice, experimentally induced thymic lymphomas were instrumental in early studies showing that the thymus is a primary immune organ and the site of T-cell development (reviewed by Yefenof, 1999) . In addition, these mouse models provided an important tool for the identification of oncogenes and tumor suppressors, leading to the concept of tumor development as a multistep process (Yefenof, 1999) . In the current model, at least two independent proto-oncogenes and/or tumor suppressors have to be mutated in order to allow cellular transformation (Hanahan and Weinberg, 2000) . One potential tumor suppressor gene is the death receptor CD95 that can potently induce apoptosis, but, when inactivated, may contribute to autoimmune disorders and tumor development (Reichmann, 2002) .
Apoptosis mediated by death receptors such as CD95 is initiated upon binding of its respective ligand, which induces receptor oligomerization (Schulze-Osthoff et al., 1998) . This event then results in the recruitment of the adaptor protein Fas-associated death domain and the initiator caspase-8 that together form a death-inducing signaling complex (DISC) (Peter and Krammer, 2003) . In the DISC, caspase-8 -and in humans also caspase-10 -is activated by dimerization and subsequent autoproteolytic cleavage. Subsequently, caspase-8 cleaves and activates caspase-3, resulting in further cleavage of several cellular targets (Fischer et al., 2003) . In some cell types, the linear progression from DISC formation to caspase-3 activation is insufficient to complete the cell death program, and amplification of the death receptor stimulus by engagement of the mitochondrial cell death pathway is required. One known mechanism by which the mitochondrial pathway is engaged following death receptor activation is through caspase-8-mediated cleavage of Bid, a proapoptotic member of the Bcl-2 family (Jiang and Wang, 2004) . The truncated Bid fragment translocates to the mitochondria, where it can induce the release of proapoptotic factors including cytochrome c, second mitochondria-derived activator of caspase and Omi/HtrA2. This intrinsic mitochondrial pathway is tightly regulated by antiapoptotic and proapoptotic members of the Bcl-2 family (Chao and Korsmeyer, 1998; Rathmell and Thompson, 2002) . When released into the cytosol, cytochrome c binds to Apaf-1 and forms together with caspase-9 a high-molecular-weight complex, called the apoptosome. Caspase-9 subsequently activates effector caspases, such as caspase-3, and thereby amplifies signals triggered by death receptors.
Currently, the functionality of apoptotic pathways in thymic lymphoma cells is largely unknown. To get further insights into apoptotic mechanisms of thymic lymphoma, we characterized TCR-induced apoptosis in the CD4 þ CD8 þ T-cell line Thy278. We show that Thy278 cells undergo apoptosis in a timeand dose-dependent manner upon CD3 stimulation. Moreover, caspase activation is essential for apoptosis of DP thymocytes. We also provide evidence that, similar to primary thymocytes, the CD95 system is involved in TCR-induced death of Thy278 cells. Thus, Thy278 thymic lymphoma cells still harbor a functional apoptosis system that is relevant in negative selection.
Results
The phenotype of Thy278 lymphoma cells resembles primary CD4
þ CD8 þ DP thymocytes In order to investigate physiological apoptosis pathways in thymic lymphoma, we employed the mouse T-cell line Thy278. The cells are derived from a spontaneous thymic tumor arising in a mouse expressing a transgenic Va11-TCR chain (Fernandez, 2000) . First, we characterized the phenotype of the thymic lymphoma cells and analysed the expression of cell surface antigens, which serve as markers for given stages of T-cell development. To this end, Thy278 cells were subjected to three-color fluorescence-activated cell sorting (FACS) analysis and compared with primary C57BL/6 thymocytes. In the CD4/CD8 profile, immature CD4 þ CD8 þ DP and mature CD4
þ SP thymocytes were gated, and expression of CD3e, CD24, CD5 and CD69 in the two subpopulations was compared (Figure 1 ). CD24 (HSA) is a marker for immature thymocytes, whereas CD5 and CD69 are markers for positive selection. As expected, primary CD4 þ SP thymocytes showed a higher expression of CD3e, CD5 and CD69 as compared to DP thymocytes, which is consistent with the former being positively selected. In contrast, expression of CD24 was high in DP and was downregulated in SP thymocytes. The transformed Thy278 cells showed high expression of CD4, CD8a and CD24 and low expression of CD69. CD3e was expressed at higher levels compared to primary DP thymocytes, but expression was lower than in SP thymocytes. CD5 was not expressed on the surface of Thy278 cells. Thus, the surface antigen expression profile of Thy278 tumor cells is very similar to immature primary CD4 þ CD8 þ DP thymocytes.
Deletion rather than differentiation in Thy278 cells upon anti-CD3e stimulation Upon TCR engagement, normal DP thymocytes can either differentiate into CD4 þ or CD8 þ SP T cells (positive selection) or they undergo apoptosis (negative selection). To investigate whether these pathways are still functional in thymic lymphoma cells, we treated Thy278 cells with plate-bound anti-CD3e for up to 2 days and stained for TCRb, CD4 and CD8a (Figure 2a) . Already 12 h after stimulation the TCR Figure 1 Thy278 is a CD4 þ CD8 þ immature thymic T-cell lymphoma line. Single cell suspensions of C57BL/6 thymic were prepared according to standard procedures. CD4
þ SP C57BL/6 thymocytes (left panels), CD4 þ CD8 þ DP C57BL/6 thymocytes (middle panels) or Thy278 cells (right panels) were stained by threecolor FACS analysis with anti-CD4-PE and anti-CD8a-CyChrome as well as FITC-conjugated anti-CD3e, anti-CD24, anti-CD5 or anti-CD69, respectively (gray curves). The solid line shows the autofluorescence of cells.
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I Schmitz et al was downregulated on Thy278 cells, which was probably owing to endocytosis (Geisler, 2004) . Thus, Thy278 cells were efficiently stimulated by the immobilized antibody. To investigate whether this kind of stimulation induces positive or negative selection, we analysed expression of CD4 and CD8a (Figure 2b ). Stimulation with anti-CD3e induced downregulation of both CD4 and CD8a within 24 h. Importantly, Thy278 cells did not develop into SP T cells under these conditions.
Thy278 cells die by apoptosis upon anti-CD3e treatment
To investigate whether treatment with anti-CD3e indeed induces apoptosis, which is the outcome of negative selection, we investigated the occurrence of apoptotic alterations including DNA fragmentation and mitochondrial depolarization. Therefore, Thy278 cells were treated with increasing amounts of anti-CD3e antibodies, and DNA fragmentation was analysed by flow cytometry after 48 h. As shown in Figure 3a , Thy278 cells died in a dose-dependent manner upon TCR triggering. When we analysed the time course of apoptosis, DNA fragmentation, a rather late event in apoptosis, was first detected 36 h after TCR stimulation ( Figure 3b ). Loss of the mitochondrial transmembrane potential (DC M ) was found to a significant extent already after 24 h ( Figure 3c ). This is consistent with changes in DC M being an early event during apoptosis. Taken together, Thy278 tumor cells can die by apoptosis upon TCR stimulation, which parallels the behavior of primary thymocytes during negative selection in the thymus.
Caspase activation is required for apoptosis of Thy278 cells upon CD3e stimulation
Caspases are the main executioners of apoptosis (Los et al., 1999; Fuentes-Prior and Salvesen, 2004) . Therefore, we wanted to know whether caspases are activated in our cellular system. Thy278 cells were stimulated for 24, 36 or 48 h with anti-CD3e, and caspase activity was measured by a fluorescence substrate assay. We used substrates to analyse caspase-3-like (DEVDase), caspase-8-like (IETDase) and caspase-9-like (LEHDase) activities. All three activities were induced with similar kinetics, although with different intensities (Figure 4a ). The higher activity of DEVD-cleaving caspases is probably owing to the greater abundance of executioner caspases such as caspase-3 compared to initiator caspases such as caspase-8 and caspase-9. We also analysed protein expression and activation of individual caspases in our system. Thy278 cells were stimulated for up to 48 h or left untreated, and subjected to Western blot analysis using specific antibodies. As shown in Figure 4b , caspase-2, -3, -8 and -9 were expressed in Thy278 cells. Cleavage, that is, activation, of caspase-2 and caspase-9 could be observed at 36 and 48 h, whereas the active fragments of caspase-3 and caspase-8 were already detected 24 h after anti-CD3e treatment. Moreover, the inactive zymogen forms of these two caspases were significantly reduced 48 h after Apoptosis in thymic lymphoma I Schmitz et al stimulation. This might hint at an involvement of the death receptor-driven extrinsic pathway in the TCR-mediated death of Thy278 cells. In addition, we observed cleavage of the proapoptotic Bcl-2 family member Bid and ICAD (DFF45), the inhibitor of the apoptotic DNase CAD/DFF40 (Figure 4b ). These proteins are substrates for caspase-8 and caspase-3, respectively (Li et al., 1998; Sakahira et al., 1998) .
Next, we asked whether activation of caspases is essential for apoptosis of Thy278 cells. To this end, cells were treated with anti-CD3e for 36 h in the absence or presence of the pan-caspase inhibitor N-(2-quinolyl)valyl-aspartyl-(2,6-difluorophenoxy)methyl ketone (Q-VD-OPh). In addition, dimethyl sulfoxide (DMSO) was used as a vehicle control. As observed above, antiCD3e treatment efficiently induced apoptosis in Thy278 cells (Figure 5a ). This remained unchanged when DMSO was added. However, anti-CD3e-induced apoptosis was blocked in the presence of 20 mM Q-VD-OPh (Figure 5a ). Also, background apoptosis was reduced in the presence of Q-VD-OPh, suggesting that ongoing apoptosis in the culture was dependent on caspases as well.
In order to compare Thy278 cells with normal thymocytes and to clarify whether caspases are also required for TCR-induced apoptosis of primary cells, we employed fetal thymus organ culture (FTOC). We used 5CC7 TCR transgenic rag2 À/À mice in which clonal deletion can be induced by administration of a pigeon cytochrome c (PCC) peptide (Sasada and Reinherz, 2001 ). Fetuses were dissected on day 15.5 of embryonic development, and thymic lobes were cultured for 5 additional days. When analysed for CD4 and CD8 expression, 65% of the thymocytes were at the DP stage (Figure 5b ). Addition of 100 nM PCC peptide 18 h before analysis resulted in a reduction of the DP population down to 22% (Figure 5c ). In the presence of 20 mM Q-VD-OPh, the percentage of DP thymocytes was slightly higher compared to the medium control (Figure 5d) . Importantly, addition of 20 mM Q-VD-OPh 4 h before the addition of the PCC peptide blocked antigen-induced deletion of DP thymocytes (Figure 5e ). Addition of the solvent DMSO alone 
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CD95L/FasL contributes to TCR-mediated apoptosis of Thy278 cells
Normal thymocytes are largely sensitive towards CD95-mediated apoptosis (Matiba et al., 1997) . In order to analyse whether this death receptor pathway is involved in apoptosis of Thy278 cells upon TCR stimulation, we first investigated the expression of the CD95L/FasL on Thy278 cells. Unstimulated Thy278 cells did not express detectable levels of CD95L/FasL, as measured by indirect immunofluorescence labeling and FACS analysis (Figure 6a ). However, we could detect CD95L/ FasL expression 12 h after TCR triggering. Expression was further increased after 36 h of anti-CD3e treatment (Figure 6a ). Therefore, CD95L/FasL induction precedes caspase activation and correlates with apoptosis of Thy278 cells.
To investigate whether the induction of the CD95L/ FasL expression is functionally relevant for TCRinduced apoptosis, we applied a blocking antibody (b) Thy278 cells were treated with the indicated concentrations of anti-CD3e antibody for 36 h. In addition, 10 mg/ml control hamster IgG, 10 mg/ml anti-CD95L or no antibody was added to the samples. Apoptosis was measured in permeabilized cells by propidium iodide staining of subdiploid DNA and subsequent FACS analysis. The experiment shown was performed in triplicate and is representative of two independent experiments. (c-f) Thymic lobes of embryonic day 15.5 fetuses of 5CC7 TCR transgenic rag2 À/À mice were used for FTOC. Fetal lobes were processed and analysed as in Figure 5 . FACS analysis of CD4 and CD8a expression is presented. Isotype-matched control IgG (10 mg/ml) (c, d) or anti-CD95L (10 mg/ml) (e, f) was added to FTOCs. Four hours after addition of antibodies, FTOCs were treated for another 18 h with 100 nM PCC peptide (d, f), or left untreated (c, e). The results are representative of three independent experiments. Apoptosis in thymic lymphoma I Schmitz et al strategy. Thy278 cells were treated for 36 h with different concentrations of anti-CD3e antibodies in the absence or presence of an anti-CD95L monoclonal antibody or an immunoglobulin (Ig)G control. Almost 50% of the cells died already with 2.5 mg/ml anti-CD3e by apoptosis when no antibody or a control hamster IgG was added (Figure 6b ). At concentrations of 5-20 mg/ml anti-CD3e-induced apoptosis rates increased to slightly above 50%. However, in the presence of an anti-CD95L antibody, apoptosis was reduced to about 35% at anti-CD3e concentrations from 2.5 to 20 mg/ml. Thus, anti-CD3e-induced apoptosis is at least in part mediated by the CD95/Fas system. Next, we addressed the contribution of the CD95/Fas system to negative selection in primary thymocytes. To this end, we used blocking anti-CD95L antibodies in FTOC. In the presence of an isotype-matched control IgG, 46% of the thymocytes were in the DP stage (Figure 6c ). In the presence of the control antibody and 100 nM PCC, the DP population was reduced down to about 14% (Figure 6d ). Addition of anti-CD95L antibody alone resulted in 65% of DP thymocytes, suggesting that constitutively ongoing apoptosis of DP thymocytes was reduced (Figure 6e ). In the presence of blocking anti-CD95L antibodies and 100 nM of the deleting PCC peptide, 34% of thymocytes were still in the DP stage (Figure 6f ). Thus, CD95L clearly mediates clonal deletion not only in transformed Thy278 cells but also in primary thymocytes.
CD95-mediated apoptosis in Thy278 lymphoma cells requires inhibition of de novo protein synthesis
Finally, we wanted to address the question why TCRinduced apoptosis required a prolonged incubation time for 36-48 h, even though CD95L expression was already detected 12 h after cell stimulation (see Figure 6a ). To this end, CD95 expression on Thy278 cells was first analysed by flow cytometry. Thy278 lymphoma cells constitutively expressed CD95 on their cell surface (Figure 7a ). CD95 expression levels were slightly increased when cells were stimulated with anti-CD3e. Next, we analysed sensitivity of Thy278 cells towards CD95-mediated apoptosis upon stimulation with recombinant CD95L. Surprisingly, Thy278 cells were completely resistant against CD95L treatment (Figure 7b ). However, resistance could be overcome when protein synthesis was blocked by the addition of 5 mg/ml cycloheximide, which alone had only a minor toxic effect (Figure 7b ). This was also reflected by the analysis of caspase processing and cleavage of caspase substrates. Cleavage of caspase-3, caspase-8 and Bid was observed only when CD95L was given to the cells in combination with cycloheximide; however, when given separately they did not induce processing (Figure 7c) . Importantly, cycloheximide treatment reduced expression of the antiapoptotic molecules c-FLIP and Bcl-xL (Figure 7c ). We reasoned that these antiapoptotic factors prevent CD95L-induced apoptosis at early time points after TCR stimulation. When anti-CD3e stimulated Thy278 cells were analysed for the expression of c-FLIP and Bcl-x L , we found that both proteins were downregulated after 36 and 48 h of TCR stimulation (Figure 7d ). In summary, TCR-induced apoptosis is functional and correlates with upregulation of CD95L and downregulation of c-FLIP and Bcl-x L in Thy278 thymic lymphoma cells.
Discussion
In the present study, we investigated the apoptotic pathways in thymic lymphoma cells, with a particular focus on TCR-induced apoptosis as a paradigm of thymocyte negative selection. Thy278 thymic lymphoma cells that were employed in this study show a CD3e
low phenotype that is characteristic of immature DP thymocytes. When treated with anti-CD3e antibodies, Thy278 cells downregulate TCRb, CD4 and CD8 and do not develop into CD4 þ or CD8 þ SP cells, which is in accordance with the apoptosis of primary autoreactive thymocytes during negative selection. Direct quantification of apoptosis revealed that Thy278 cells die in a dose-and timedependent manner upon TCR stimulation. Moreover, we show that TCR-mediated apoptosis in Thy278 cells is dependent on caspase activation and that CD95L plays a role in deletion of these cells. Caspases and CD95L are also crucial for deletion of primary thymocytes in a TCR-transgenic FTOC system. Thus, despite their transformed phenotype, Thy278 cells behave like primary thymocytes with respect to TCR-induced apoptosis. Intriguingly, direct triggering of the CD95 receptor did not lead to apoptosis in Thy278 cells. CD95-mediated apoptosis was observed only when de novo protein synthesis was blocked.
Malignant transformation is a multistep process during which cancer cells acquire different capabilities such as independence from growth and survival signals, limitless replicative potential and, importantly, resistance towards apoptosis signals (Hanahan and Weinberg, 2000) . Normal thymocytes readily die upon engagement of the CD95 death receptor. However, in tumor cells, sensitivity towards CD95-mediated apoptosis is often decreased (Reichmann, 2002) . Therefore, the lack of CD95 responsiveness in Thy278 cells may have been a crucial event in the transformation of these cells from a normal DP thymocyte, which usually has a half-life of a few days (Starr et al., 2003) . CD95 sensitivity could be restored in Thy278 cells by inhibition of protein synthesis. This correlated with a downregulation of c-FLIP and Bcl-x L in anti-CD3e-treated cells. Both of these molecules are known for their antiapoptotic activity and short half-life (Kirchhoff et al., 2000; Sohn et al., 2006) . Thus, in Thy278 cells, sensitivity towards CD95-mediated apoptosis is regulated by the level of intracellular signal transduction. Resistance towards CD95 as a cancer progressive event has also been reported in B-cell lymphoma and adult T-cell leukemia (Maeda et al., 1999; Muschen et al., 2002) . However, in B cells, CD95 unresponsiveness is owing to somatic mutations of the CD95 gene itself, which occur during the germinal center reaction and lead to a non-functional receptor. Also a number of non-lymphoid tumors show reduced CD95 responsiveness owing to downregulation of receptor expression (reviewed by Igney and Krammer, 2002) . DP thymocyte cell lines have been used previously to delineate signaling pathways of thymocyte development (Kaye and Ellenberger, 1992; Groves et al., 1995; Kovalik et al., 1996; Fernandez, 2000; Nishida et al., 2004) . However, all of these studies, except one, dealt with thymocyte maturation, that is, positive selection or lineage commitment. The study by Kovalik et al. (1996) investigated negative selection, but the molecular mechanisms of thymocyte death were not analysed. Thus, our study provides first insights into molecular Apoptosis in thymic lymphoma I Schmitz et al mechanisms of apoptosis in a DP tumor cell line. In this regard, Thy278 cells may serve as a biochemical model system for apoptotic signaling during negative selection.
With respect to negative selection, our data obtained in Thy278 cells and in FTOC are in line with other reports that implicated caspase activation in negative selection (Alam et al., 1997; Clayton et al., 1997; Izquierdo et al., 1999) . However, a subsequent study by Doerfler et al. (2000) challenged the view that caspases are necessary for negative selection. This, however, may be related to the short half-life of the caspase inhibitor Z-Val-Ala-DL-Asp (OMe)-Fluoromethylketone (zVAD-fmk) that was used in some of these studies. We also observed only a minor reduction of negative selection in the Thy278 model and in FTOC using zVAD-fmk (data not shown). In contrast, the pancaspase inhibitor Q-VD-OPh, which has an improved stability as well as an increased potency and specificity compared to zVAD-fmk (Caserta et al., 2003; Fischer and Schulze-Osthoff, 2005) , completely blocked negative selection and reduced spontaneous apoptosis. Thus, our results together with the data by others (Alam et al., 1997; Clayton et al., 1997; Izquierdo et al., 1999) clearly argue for a requirement of caspases in negative selection.
The role of CD95 in negative selection is controversial. This is owing to the fact that selection processes seem not be affected in mice carrying a mutation in the CD95/Fas (lpr) and CD95L/FasL (gld) genes (Wadsworth et al., 1990; Sidman et al., 1992; Moulian and Berrih-Aknin, 1998) . In contrast, blocking the activity of the CD95 ligand by a CD95-Fc construct resulted in impaired negative selection (Castro et al., 1996) . It should be noted that the lpr mutation does not totally abolish CD95 signaling. Although DISC formation is impaired in lpr þ cells (Martin et al., 1999), CD95 lpr is still capable of inducing nuclear factor (NF)-kB (Legembre et al., 2004) . Interestingly, NF-kB, which is usually regarded as an antiapoptotic factor, was shown to be required for apoptosis of DP thymocytes (Hettmann et al., 1999) . Thus, it remains possible that CD95 lpr transduces an apoptotic signal into DP thymocytes during negative selection. As lpr is a leaky mutation, we used blocking anti-CD95L antibodies and TCR transgenic animals with a CD95 wild-type background in FTOC. Using this experimental setup, we demonstrate here a role for the CD95 system in deletion of both thymocytes with an MHC class II-restricted 5CC7 TCR and Thy278 thymic lymphoma cells. Therefore, the CD95 system provides one possible mechanism for deletion of autoreactive thymocytes during negative selection. Furthermore, although the mechanism of TCR-induced apoptosis is still functional in Thy278 cells, increased resistance to direct effects of CD95 signaling might contribute to development of thymic lymphoma.
Materials and methods
Mice and cell culture C57BL/6 and 5CC7 TCR transgenic rag2 À/À (Taconics, Germantown, NY, USA) mice were maintained and bred under barrier conditions at the animal facility of the University of Du¨sseldorf. All animal experiments were approved and carried out according to the institutional and national guidelines. Mice were killed, and thymic single cell suspensions were prepared for the indicated experiments. The mouse CD4 þ
CD8
þ T-cell line Thy278 is derived from a spontaneous thymic lymphoma arising in a mouse expressing a Va11-TCRa transgene (Berg et al., 1988; Fernandez, 2000) . The cells were cultured in RPMI 1640 (PAA Laboratories, Co¨lbe, Germany) supplemented with 10% fetal calf serum (BioWest, Frickenhausen, Germany), 2 mM glutamine, 50 mM b-mercaptoethanol and 50 mg/ml of each penicillin and streptomycin (Invitrogen, Karlsruhe, Germany).
Antibodies and reagents
The following antibodies from BD Pharmingen (Heidelberg, Germany) were used for FACS analysis: R-phycoerythrin (R-PE)-or CyChrome-conjugated anti-CD3e (2C11), anti-CD4 (L3T4), fluorescein isothiocyanate (FITC)-or CyChrome-conjugated anti-CD8a (Ly-2), FITC-conjugated anti-CD24 (M1/69), PE-conjugated anti-CD5 (53-7.3), FITCconjugated anti-CD69 (H1.2F3), PE-conjugated anti-CD95 (Jo2) and CyChrome-conjugated anti-TCRb (H57-597). For blocking studies, anti-FasL (MFL3), hamster IgG1 (G235-2356) and mouse IgG1 (107.3) antibodies were purchased from BD Pharmingen, and the anti-FasL clone 3C82 was from BioCheck (Mu¨nster, Germany). The antibodies used for Western blotting were b-actin (AC-74; Sigma, Deisenhofen, Germany), Bcl-x (#610212; BD Pharmingen), Bid (AF860; R&D Systems, Wiesbaden, Germany), caspase-2 (F7; Santa Cruz Biotechnology, Santa Cruz, CA, USA), caspase-3 (clone 46; BD Pharmingen), caspase-8 (1G12; Alexis, Gru¨nberg, Germany) and caspase-9 (#9504; Cell Signaling, Frankfurt, Germany), c-FLIP (Dave-2; Alexis), ICAD (#550736; BD Pharmingen) and tubulin (DM1A; Sigma). The horseradish peroxidase-coupled (HRPO)-conjugated goat anti-rabbit IgG was from Santa Cruz Biotechnology (sc-2054). The HRPO-conjugated goat anti-rat IgG, donkey anti-goat IgG, goat anti-mouse IgG1, IgG2a and IgG2b were from Southern Biotechnology Associates (Birmingham, AL, USA). The pan-caspase inhibitor Q-VD-OPh was purchased from MP Biomedicals (Irvine, CA, USA). JC-1 (5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethylbenzimidazolylcarbocyanine iodide) was from Molecular Probes (Eugene, OR, USA). Flag-tagged CD95L was a kind gift from Dr Harald Wajant (Wu¨rzburg, Germany). All other chemicals used were of analytical grade and were purchased from Merck (Darmstadt, Germany) or Sigma.
FACS assays
Cell surface stainings, cytotoxicity assays and determination of mitochondrial membrane potential were performed as described previously (Schmitz et al., 2004) . For assaying apoptosis, 1 Â 10 6 cells were stimulated in 24-well plates (if not stated otherwise) with 20 mg/ml anti-CD3e (clone 145-2C11) or left untreated for the indicated times at 371C.
Caspase activity assay 2.5 Â 10 6 Thy278 cells were seeded in six-well plates and either stimulated with plate-bound anti-CD3e antibody or left untreated. Cells were incubated for the indicated time periods, washed with phosphate-buffered saline (PBS) and lysed in Triton-based lysis buffer (TLB) (20 mM Tris/HCl, pH 7.4, 1% Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride and 1 mg/ml of each leupeptin, antipain, chymostatin and pepstatin A). A 10 ml portion of lysate was adjusted with caspase buffer (50 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid, pH 7.3, 10% sucrose, 100 mM NaCl, 0.1% 3-[(3-cholamido propyl)-dimethylammonio]-2-hydroxy-1-propanesulfonic acid, 10 mM dithiothreitol) to a total volume of 100 ml and supplemented with 50 mM fluorogenic caspase substrate. Substrates used were DEVD-AMC (caspase-3-like activity), IETD-AMC (caspase-8-like activity) and LEHD-AMC (caspase-9-like activity) (purchased from Biomol, Hamburg, Germany). The reaction was incubated at 371C and measured in a Lambda Fluro 320 Plus fluorometer (Biotek, Bad Friedrichshall, Germany). The fluorogenic cleavage assay was performed in triplicate.
Western blot analysis
For Western blot analysis, cells were lysed in TLB buffer. A 20mg portion of postnuclear supernatant protein as determined by the BCA method (Pierce Biotechnology, Rockford, IL, USA) was separated by 12% SDS-PAGE, blotted onto a nitrocellulose membrane (Amersham, Freiburg, Germany) and blocked with 5% non-fat dry milk in PBS/ Tween (0.05% Tween 20 in PBS). After washing with PBS/ Tween, the blots were incubated overnight with specific antibodies at 41C. Blots were washed again with PBS/Tween, incubated with HRPO-coupled isotype-specific secondary antibodies (1:20 000) for 1 h at room temperature, washed again and developed with a chemiluminescence reagent (Amersham). For stripping, blots were incubated for 15 min in Re-Blot mild solution (Chemikon, Hofheim, Germany) according to the manufacturer's procedure. The blots were washed three times for 10 min in PBS/Tween and blocked again in 5% non-fat drymilk.
FTOC
The 5CC7 TCR binds a PCC peptide (aa 88-104 KAER-ADLIAYLKQATAK) in the context of the I-E k MHC class II molecule. The PCC peptide was synthesized by standard solid phase methods, purified by high-pressure liquid chromatography and analysed by mass spectrometry for purity and correct molecular composition. Fetuses of 5CC7 TCR transgenic rag2 À/À mice were dissected at day 15.5, with the day of the vaginal plug counted as day 1. Fetal lobes were removed and cultured in 24-well Transwell dishes (Costar, Cambridge, MA, USA) using 0.4 ml of AIM V medium (Gibco, Rocksville, MD, USA). The samples were incubated in a humidified atmosphere with 5% CO 2 for 4-5 days at 371C. On day 5, FTOC were preincubated with blocking reagents for 4 h or left untreated. Subsequently, PCC peptide was added at the concentrations indicated and incubated overnight. For harvesting, lobes were ground between frosted glass slides in PBS/2% BSA/0.05% NaN 3 , washed and used for FACS analysis.
